Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
AbbVie has accelerating defensive healthcare momentum, with Q1 2026 revenue of $15.0B, adjusted EPS up 7.7%, raised full-year 2026 EPS guidance to $14.08-$14.28, FDA approval of DECNUPAZ, filings for SKYRIZI and upadacitinib, clinical data readouts, and about 12.7% price strength over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash Generation ⢠Negative Equity ⢠Elevated Leverage ABBV delivers strong margins and cash flow, but heavy debt, negative equity, weak liquidity, high payout obligations, and elevated valuation create significant downside risk.
Price Behavior
Key Price Behavior Insights: ⢠Momentum weakening ⢠Key range ⢠Consecutive declines Support Level: $250â$246 Resistance Level: $264â$266 ABBV remains above its last-month average but is weakening after a 3.6% pullback and three straight declines, with $264â$266 resistance and $250â$246 support defining the near-term trade.
Sentiment & News
Key News Insights: ⢠Immunology Growth ⢠Apogee Acquisition ⢠Institutional Buying AbbVie's strong growth from Skyrizi, Rinvoq, and acquisitions offsets Humira erosion, supporting resilient fundamentals despite near-term cost and segment headwinds.
AI Summary
AbbVie's post-Humira transition is workingâSkyrizi and Rinvoq now anchor growth and cash flowâbut at ~$260, investors should demand continued immunology momentum and neuroscience diversification to offset high leverage and Apogee's EPS dilution through 2027; hold/add only if execution supports a break above $264â266.
Description
AbbVie Inc. is a global pharmaceutical company that discovers, develops, manufactures and markets prescription drugs across immunology, oncology, neuroscience, virology and eye care. Its portfolio includes established biologics and small-molecule therapies for conditions such as autoimmune diseases, cancer, hepatitis C, Parkinsonâs and glaucoma, alongside specialty products for endocrine and gastrointestinal disorders. The company was incorporated in 2012, is headquartered in North Chicago, Illinois, and maintains external research collaborations, including an agreement with Dragonfly Therapeutics.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 26 | Jul 3 | ABBV | AbbVie Inc. | AbbVie has accelerating defensive healthcare momentum, with Q1 2026 revenue of $15.0B, adjusted EPS up 7.7%, raised full-year 2026 EPS guidance to $14.08-$14.28, FDA approval of DECNUPAZ, filings for SKYRIZI and upadacitinib, clinical data readouts, and about 12.7% price strength over 21 trading days. | Closed | +3.0% |
| Sep 29 | Oct 6 | ABBV | AbbVie Inc. | AbbVie beat Q2 2025 earnings with raised full-year guidance based on strong sales of key drugs, pipeline advancements, and a 6% dividend increase. The ~6% recent price rise and moderate upward technical momentum, despite nearing resistance, point to moderate near-term capital appreciation potential. | Closed | +3.1% |